|
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
||
|
|
|
Item 2.02 |
Results of Operations and Financial Condition.
|
Item 7.01 |
Regulation FD Disclosure
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
|
Press Release of Chembio Diagnostics, Inc., dated November 3, 2022
|
||
99.2 |
Script of conference call of Chembio Diagnostics, Inc. held on November 3, 2022
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
Chembio Diagnostics, Inc.
|
||
Dated: November 3, 2022
|
By:
|
/s/ Richard L. Eberly
|
Chief Executive Officer and President
|
• |
Achieved third quarter 2022 total revenue of $11.2 million including product revenue of $10.9 million, representing product revenue growth of 16% compared to the prior year period:
|
• |
U.S. product revenue of $4.8 million grew 361% compared to the
prior year period
|
• |
Awarded $3.2 million contract from the CDC for development and clinical validation of Dual-Path Platform (DPP) Syphilis Treponemal Nontreponemal (TNT)
Assay
|
• |
Launched E-Commerce platform commercialization of Sure Check HIV Self-Test in Brazil and in the U.K. through Amazon
|
• |
Completed initial test production in the Chembio Malaysia facility
|
•
|
Focus on higher margin business in growth markets
|
•
|
Lower manufacturing costs
|
•
|
Reduce infrastructure costs
|
•
|
Strategic review of non-core businesses and assets
|
•
|
The ongoing healthcare and economic impacts of COVID-19 on the global customer base for the Company’s non‑COVID-19 products continue to
negatively affect the timing and rate of recovery of the Company’s revenues from those products.
|
•
|
Although the Company has entered into agreements to distribute third-party COVID-19 products in the United States, its ability to sell those
products could be constrained because of staffing and supply chain limitations affecting the suppliers of those products.
|
For the three months ended
|
For the nine months ended
|
|||||||||||||||
September 30, 2022
|
September 30, 2021
|
September 30, 2022
|
September 30, 2021
|
|||||||||||||
REVENUES:
|
||||||||||||||||
Product revenue
|
$
|
10,844,003
|
$
|
9,371,160
|
$
|
38,229,605
|
$
|
17,327,204
|
||||||||
R&D revenue
|
50,000
|
441
|
76,219
|
1,107,808
|
||||||||||||
Government grant income
|
-
|
2,400,000
|
-
|
8,030,000
|
||||||||||||
License and royalty revenue
|
306,145
|
286,843
|
872,365
|
779,901
|
||||||||||||
TOTAL REVENUES
|
11,200,148
|
12,058,444
|
39,178,189
|
27,244,913
|
||||||||||||
COSTS AND EXPENSES:
|
||||||||||||||||
Cost of product revenue
|
9,658,678
|
7,902,819
|
32,969,388
|
15,490,956
|
||||||||||||
Research and development expenses
|
1,871,113
|
3,442,044
|
5,567,169
|
9,102,363
|
||||||||||||
Selling, general and administrative expenses
|
5,551,362
|
5,947,327
|
17,747,613
|
18,033,748
|
||||||||||||
Impairment, restructuring, severance and related costs
|
110,250
|
396,740
|
3,153,429
|
2,440,983
|
||||||||||||
TOTAL COSTS AND EXPENSES
|
17,191,403
|
17,688,930
|
59,437,599
|
45,068,050
|
||||||||||||
LOSS FROM OPERATIONS
|
(5,991,255
|
)
|
(5,630,486
|
)
|
(20,259,410
|
)
|
(17,823,137
|
)
|
||||||||
OTHER EXPENSE:
|
||||||||||||||||
Interest expense, net
|
(707,549
|
)
|
(735,336
|
)
|
(2,169,525
|
)
|
(2,175,188
|
)
|
||||||||
LOSS BEFORE INCOME TAXES
|
(6,698,804
|
)
|
(6,365,822
|
)
|
(22,428,935
|
)
|
(19,998,325
|
)
|
||||||||
Income tax (provision) benefit
|
-
|
(28
|
)
|
(6,606
|
)
|
67,928
|
||||||||||
NET LOSS
|
$
|
(6,698,804
|
)
|
$
|
(6,365,850
|
)
|
$
|
(22,435,541
|
)
|
$
|
(19,930,397
|
)
|
||||
Basic and diluted loss per share
|
$
|
(0.21
|
)
|
$
|
(0.24
|
)
|
$
|
(0.73
|
)
|
$
|
(0.89
|
)
|
||||
Weighted average number of shares outstanding, basic and diluted
|
32,274,664
|
26,701,546
|
30,862,982
|
22,361,899
|
(Unaudited)
|
||||||||
September 30, 2022
|
December 31, 2021
|
|||||||
- ASSETS -
|
||||||||
CURRENT ASSETS:
|
||||||||
Cash and cash equivalents
|
$
|
21,055,026
|
$
|
28,772,892
|
||||
Accounts receivable, net of allowance for doubtful accounts of $242,354 and $243,042 as of September 30, 2022 and December 31, 2021,
respectively
|
5,252,573
|
11,441,107
|
||||||
Inventories, net
|
8,465,210
|
12,920,451
|
||||||
Prepaid expenses and other current assets
|
12,509,604
|
2,096,399
|
||||||
TOTAL CURRENT ASSETS
|
47,282,413
|
55,230,849
|
||||||
FIXED ASSETS:
|
||||||||
Property, Plant and Equipment, net
|
8,813,699
|
8,556,773
|
||||||
Finance lease right-of-use asset, net
|
154,826
|
191,870
|
||||||
TOTAL FIXED ASSETS, net
|
8,968,525
|
8,748,643
|
||||||
OTHER ASSETS:
|
||||||||
Operating lease right-of-use assets, net
|
5,639,763
|
5,891,906
|
||||||
Goodwill
|
-
|
3,022,787
|
||||||
Deposits and other assets
|
289,203
|
358,010
|
||||||
TOTAL ASSETS
|
$
|
62,179,904
|
$
|
73,252,195
|
||||
- LIABILITIES AND STOCKHOLDERS’ EQUITY -
|
||||||||
CURRENT LIABILITIES:
|
||||||||
Accounts payable and accrued liabilities
|
$
|
18,050,498
|
$
|
13,127,993
|
||||
Operating lease liabilities
|
910,100
|
886,294
|
||||||
Finance lease liabilities
|
75,279
|
68,176
|
||||||
Current portion of long-term debt
|
18,993,535
|
1,200,000
|
||||||
TOTAL CURRENT LIABILITIES
|
38,029,412
|
15,282,463
|
||||||
OTHER LIABILITIES:
|
||||||||
Long-term operating lease liabilities
|
5,655,468
|
5,976,151
|
||||||
Long-term finance lease liabilities
|
96,529
|
139,678
|
||||||
Long-term debt, net
|
10,684
|
17,589,003
|
||||||
TOTAL LIABILITIES
|
43,792,093
|
38,987,295
|
||||||
STOCKHOLDERS’ EQUITY:
|
||||||||
Preferred stock – 10,000,000 shares authorized, none issued or outstanding
|
-
|
-
|
||||||
Common stock - $0.01 par value; 100,000,000 shares authorized; 35,392,496 shares and 30,056,929 shares issued at September 30, 2022 and
December 31, 2021, respectively
|
354,406
|
301,050
|
||||||
Additional paid-in capital
|
171,448,870
|
165,772,636
|
||||||
Accumulated deficit
|
(153,445,401
|
)
|
(131,009,860
|
)
|
||||
Treasury stock 48,057 shares at cost as of September 30, 2022 and December 31, 2021, respectively
|
(206,554
|
)
|
(206,554
|
)
|
||||
Accumulated other comprehensive loss
|
(358,510
|
)
|
(592,372
|
)
|
||||
TOTAL STOCKHOLDERS’ EQUITY
|
17,792,811
|
34,264,900
|
||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
|
$
|
61,584,904
|
$
|
73,252,195
|
September 30,
|
September 30,
|
|||||||
2022
|
2021
|
|||||||
Net cash used in operating activities
|
(9,751,666
|
)
|
(24,150,484
|
)
|
||||
Net cash used in investing activities
|
(1,480,662
|
)
|
(1,420,249
|
)
|
||||
Net cash provided by financing activities
|
3,531,071
|
38,646,767
|
||||||
Effect of exchange rate changes on cash
|
(16,609
|
)
|
(138,335
|
)
|
||||
DECREASE IN CASH AND CASH EQUIVALENTS
|
(7,717,866
|
)
|
12,937,699
|
|||||
Cash and cash equivalents - beginning of the period
|
28,772,892
|
23,066,301
|
||||||
Cash and cash equivalents - end of the period
|
$
|
21,055,026
|
$
|
36,004,000
|